Biohaven Secures $600 Million Non-Dilutive Funding from Oberland Capital for Rare Disease Drug Development
• Biohaven Ltd. has entered into a $600 million non-dilutive funding agreement with Oberland Capital, with an initial $250 million tranche expected by April 30, 2025.
• The investment will support Biohaven's clinical trials and commercialization efforts for troriluzole, a potential first-ever treatment for spinocerebellar ataxia (SCA), a group of rare, progressively debilitating genetic disorders.
• Following FDA approval of troriluzole, Biohaven can access an additional $150 million, with another $200 million available for strategic acquisitions, while Oberland will receive milestone payments and tiered royalties.
© Copyright 2025. All Rights Reserved by MedPath